Research Papers:

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Nobuhiro Hanai _, Michi Sawabe, Takahiro Kimura, Hidenori Suzuki, Taijiro Ozawa, Hitoshi Hirakawa, Yujiro Fukuda and Yasuhisa Hasegawa

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:37008-37016. https://doi.org/10.18632/oncotarget.26438

Metrics: PDF 1164 views  |   HTML 2383 views  |   ?  


Nobuhiro Hanai1, Michi Sawabe1,2, Takahiro Kimura1,3, Hidenori Suzuki1, Taijiro Ozawa1,4, Hitoshi Hirakawa1,5, Yujiro Fukuda1,6 and Yasuhisa Hasegawa1,7

1Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan

2Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan

3Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Nara, Japan

4Department of Otolaryngology, Toyohashi Municipal Hospital, Aichi, Japan

5Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

6Department of Otolaryngology, Kawasaki Medical School, Okayama, Japan

7Department of Head and Neck Surgery and Otolaryngology, Asahi University Hospital, Gifu, Japan

Correspondence to:

Nobuhiro Hanai, email: [email protected]

Keywords: modified Glasgow prognostic score; high-sensitivity modified Glasgow prognostic score; head and neck cancer; C-reactive protein; survival

Received: August 06, 2018     Accepted: November 26, 2018     Published: December 11, 2018


Background: There is increasing evidence that the inflammatory indices of modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) play important roles in predicting the survival in many cancer; however, evidence supporting such an association in head and neck cancer (HNC) is scarce.

Materials and Methods: We evaluated the impact of the mGPS and HS-mGPS on the overall survival (OS) in 129 patients with HNC treated at Aichi Cancer Center Central Hospital from 2012-2013. The mGPS was calculated as follows: mGPS of 0, C-reactive protein (CRP) ≤1.0 mg/dl; 1, CRP >1.0 mg/dl; 2, CRP>1.0 mg/dl and albumin <3.5 mg/dl. Regarding the HS-mGPS, the CRP threshold level was set as 0.3 mg/dl. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models after adjusting for potential confounders.

Results: The prognosis of HNC worsened significantly as both the mGPS and HS-mGPS increased in a univariate analysis. After adjusting for covariates, the HS-mGPS was significantly associated with the OS (adjusted HR for HS-mGPS of 2 compared to an HS-mGPS of 0 [HRscore2-0] 3.14 [95% CI: 1.23-8.07], Ptrend < 0.001), while the mGPS was suggested to be associated with the survival (HRscore2-0 2.37 [95% CI:0.89-6.33], Ptrend = 0.145). Even after stratification by clinical covariates, these associations persisted.

Conclusion: We conclude that the HS-mGPS is useful as an independent prognostic factor in HNC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26438